Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT8 | Q16880 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102529 | 0.86 | PARP1 (0.40) | UGT8PARP1PARP2IKBKBPTPN11 | |
| SCHEMBL103930 | 0.80 | HTR4 (0.33) | HTR4CSF1RKITSLC18A3HRH3 | |
| SCHEMBL103081 | 0.78 | MEN1 (0.38) | UGT8HTR4CSF1RKITSLC18A3 | |
| SCHEMBL106858 | 0.76 | PDE4B (0.40) | DRD2HRH3 | |
| SCHEMBL169493 | 0.70 | ME2 (0.38) | CSF1RKITDRD2 | |
| SCHEMBL27662275 | 0.69 | HTR4 (0.42) | HTR4SLC18A3HRH3 | |
| SCHEMBL905365 | 0.69 | TACR1 (0.49) | PARP1PARP2HTR1ADRD2HTR2A | |
| SCHEMBL27658356 | 0.68 | SMO (0.40) | IKBKB | |
| SCHEMBL27658351 | 0.68 | HRH4 (0.40) | IKBKBHRH3 | |
| SCHEMBL103078 | 0.67 | FLT1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | UGT8 899/4885PARP1 4088/4885PARP2 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.